Clinicopathological association of programmed death-ligand 1 (PD-L1) expression in uterine cervical carcinomas: A cross-sectional observational study
Indian Journal of Pathology and Microbiology · 2025
DOI: 10.4103/ijpm.ijpm_572_24 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Indian Journal of Pathology and Microbiology, 2025. Verfasst von Md Ashab Anwer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, All India Institute of Medical Sciences, Patna, Bihar, India. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Programmed death ligand ( PD-L1 ) binds to its receptor PD-1 on T-cells and inhibits the immune response of T-lymphocytes. Cancer cells evade immune surveillance by upregulating PD-L1 expression, leading to tumor progression. Anti- PD-L1 immunotherapy has emerged as a new treatment modality in various solid carcinomas. Food and Drug Administration (FDA) has approved PD-1 / PD-L1 axis immunotherapy for immunohistochemically PD-L1 positive cervical cancer. In India, cervical cancer accounts for approximately 17% of all cancer deaths among women between 30 and 70 years. More than three-fourths of patients are diagnosed at an advanced stage. Materials and Methods: A hospital-based, cross-sectional prospective study was conducted over five years. 119 histologically proven cases of cervical carcinoma meeting the inclusion criteria were included in the study. Sections were stained with PD-L1 antibody clone SP263 as recommended on Ventana Benchmark XT.
Results
Of 119 cases, PD-L1 expression was found in 42 cases (35%). Patients over 45 years (75.6%) had higher PD-L1 positivity compared to those under 45 years (24.4%). 31% of squamous cell carcinoma was PD-L1 positive compared to adenocarcinoma (29%). PD-L1 expression was more frequent in poorly differentiated carcinoma (37.5%).
Conclusion
A significant proportion of cervical cancers expressed PD-L1 . Increased PD-L1 expression was seen with increasing age and poorly differentiated histological grade. Anti- PD-L1 immunotherapy can be an option in PD-L1 -positive cervical cancer. The findings of our study support the requirement for further investigation of anti- PD-L1 immunotherapy for the treatment of PD-L1 -positive cervical carcinomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, All India Institute of Medical Sciences, Patna, Bihar, India.
Zitieren
APA
Anwer, M. A., Sinha, R., Bharti, S., Surabhi, Kumar, T., & Singh, A. (2025). Clinicopathological association of programmed death-ligand 1 (PD-L1) expression in uterine cervical carcinomas: A cross-sectional observational study. Indian Journal of Pathology and Microbiology. https://doi.org/10.4103/ijpm.ijpm_572_24
Vancouver
Anwer MA, Sinha R, Bharti S, Surabhi, Kumar T, Singh A. Clinicopathological association of programmed death-ligand 1 (PD-L1) expression in uterine cervical carcinomas: A cross-sectional observational study. Indian Journal of Pathology and Microbiology. 2025. doi:10.4103/ijpm.ijpm_572_24
BibTeX
@article{Anwer2025,
author = {Anwer, Md Ashab and Sinha, Ruchi and Bharti, Shreekant and Surabhi and Kumar, Tarun and Singh, Avinash},
title = {Clinicopathological association of programmed death-ligand 1 (PD-L1) expression in uterine cervical carcinomas: A cross-sectional observational study},
journal = {Indian Journal of Pathology and Microbiology},
year = {2025},
doi = {10.4103/ijpm.ijpm_572_24}
}
EUVIMED